REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO (RGNX) has announced its participation in multiple upcoming investor conferences throughout May and June 2025. The company will be present at five major healthcare and biotech events:
- BofA Securities Health Care Conference in Las Vegas (May 13)
- RBC Global Healthcare Conference in New York (May 20)
- H.C. Wainwright BioConnect in New York (May 20)
- Stifel Virtual Ophthalmology Forum (May 27)
- UBS Spring Biotech Conference in New York (June 24)
Select presentations and fireside chats will be available via webcast on REGENXBIO's website, with recordings accessible for approximately 30 days after each event.
REGENXBIO (RGNX) ha annunciato la sua partecipazione a numerose conferenze per investitori previste tra maggio e giugno 2025. L'azienda sarà presente a cinque importanti eventi nel settore sanitario e biotecnologico:
- BofA Securities Health Care Conference a Las Vegas (13 maggio)
- RBC Global Healthcare Conference a New York (20 maggio)
- H.C. Wainwright BioConnect a New York (20 maggio)
- Stifel Virtual Ophthalmology Forum (27 maggio)
- UBS Spring Biotech Conference a New York (24 giugno)
Alcune presentazioni e sessioni informali saranno disponibili in webcast sul sito di REGENXBIO, con registrazioni accessibili per circa 30 giorni dopo ogni evento.
REGENXBIO (RGNX) ha anunciado su participación en varias conferencias para inversores que se llevarán a cabo en mayo y junio de 2025. La compañía estará presente en cinco importantes eventos del sector sanitario y biotecnológico:
- Conferencia de Salud de BofA Securities en Las Vegas (13 de mayo)
- Conferencia Global de Salud de RBC en Nueva York (20 de mayo)
- H.C. Wainwright BioConnect en Nueva York (20 de mayo)
- Foro Virtual de Oftalmología de Stifel (27 de mayo)
- Conferencia de Biotecnología de Primavera de UBS en Nueva York (24 de junio)
Algunas presentaciones y charlas informales estarán disponibles vía webcast en el sitio web de REGENXBIO, con grabaciones accesibles durante aproximadamente 30 días después de cada evento.
REGENXBIO (RGNX)는 2025년 5월과 6월에 예정된 여러 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. 회사는 다섯 개의 주요 헬스케어 및 바이오테크 행사에 참석할 예정입니다:
- BofA Securities 헬스케어 컨퍼런스, 라스베이거스 (5월 13일)
- RBC 글로벌 헬스케어 컨퍼런스, 뉴욕 (5월 20일)
- H.C. Wainwright BioConnect, 뉴욕 (5월 20일)
- Stifel 가상 안과 포럼 (5월 27일)
- UBS 봄 바이오테크 컨퍼런스, 뉴욕 (6월 24일)
선택된 발표와 대화 세션은 REGENXBIO 웹사이트를 통해 웹캐스트로 제공되며, 각 행사 후 약 30일간 녹화된 영상을 시청할 수 있습니다.
REGENXBIO (RGNX) a annoncé sa participation à plusieurs conférences pour investisseurs prévues en mai et juin 2025. La société sera présente à cinq événements majeurs dans les secteurs de la santé et de la biotechnologie :
- Conférence BofA Securities Health Care à Las Vegas (13 mai)
- Conférence mondiale RBC Global Healthcare à New York (20 mai)
- H.C. Wainwright BioConnect à New York (20 mai)
- Forum virtuel d'ophtalmologie Stifel (27 mai)
- Conférence UBS Spring Biotech à New York (24 juin)
Certaines présentations et discussions informelles seront accessibles en webcast sur le site de REGENXBIO, avec des enregistrements disponibles environ 30 jours après chaque événement.
REGENXBIO (RGNX) hat seine Teilnahme an mehreren bevorstehenden Investorenkonferenzen im Mai und Juni 2025 angekündigt. Das Unternehmen wird auf fünf bedeutenden Veranstaltungen im Gesundheits- und Biotechnologiesektor vertreten sein:
- BofA Securities Health Care Conference in Las Vegas (13. Mai)
- RBC Global Healthcare Conference in New York (20. Mai)
- H.C. Wainwright BioConnect in New York (20. Mai)
- Stifel Virtual Ophthalmology Forum (27. Mai)
- UBS Spring Biotech Conference in New York (24. Juni)
Ausgewählte Präsentationen und Gesprächsrunden werden per Webcast auf der Website von REGENXBIO verfügbar sein, wobei Aufzeichnungen etwa 30 Tage nach jeder Veranstaltung abrufbar sind.
- None.
- None.
BofA Securities Health Care Conference 2025
Presentation: Tuesday, May 13, 2025 at 5:00 p.m. PT
Location:
RBC Global Healthcare Conference
Fireside Chat: Tuesday, May 20, 2025 at 11:30 a.m. ET
Location:
H.C. Wainwright BioConnect
Fireside Chat: Tuesday, May 20, 2025 at 4:00 p.m. ET
Location:
Stifel Virtual Ophthalmology Forum
Fireside Chat: Tuesday, May 27, 2025 at 9:30 a.m. ET
Location: Virtual
UBS Spring Biotech Conference
1x1 Investor Meetings: Tuesday, June 24, 2025
Location:
Live webcasts of select presentations and fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302446818.html
SOURCE REGENXBIO Inc.
FAQ
What investor conferences will REGENXBIO (RGNX) attend in May and June 2025?
Where can investors watch REGENXBIO's (RGNX) conference presentations?
Which REGENXBIO (RGNX) conference presentations will be in New York?
When is REGENXBIO's (RGNX) presentation at the BofA Securities Health Care Conference 2025?
